B+
Bull case
25%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
VNDA
VandaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+98.1
Score
AI commentary
Post-earnings news tone is positive-to-mixed: Fanapt growth, pipeline milestones, and runway support the bull case, while flat-to-down portfolio sales, HETLIOZ weakness, and higher losses temper it. The packet does not provide verified post-print market-reaction attribution, analyst revisions, or target changes; social coverage is absent. The August 6 price anchor was $5.115, but causal interpretation of the reaction remains unavailable.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-05eventQ2 2026 earnings reset: strong Fanapt, mixed portfolio resultsMedium impact
The August 5 8-K reported Fanapt net sales up 23% year over year to $36.0 million and prescriptions up 31%, but total product sales declined 4% to $50.5 million, HETLIOZ sales fell 66%, and the pretax loss widened to $62.4 million. Cash of $170 million was expected to fund operations through at least 2027. The earnings signal is therefore constructive but mixed [#SEC-8K-2026-08-05].
2026-09-30catalystBYSANTI launch and Q3 revenue captureHigh impact
BYSANTI is approved for bipolar I disorder and schizophrenia with commercial launch expected in the second half of 2026. Approximately $7 million of HETLIOZ orders shipped in late June are expected to be recognized in Q3, while NEREUS generated $1.0 million in Q2 and personal promotion is expected later in 2026 [#SEC-8K-2026-08-05].
2026-12-12eventQuimilza FDA action dateHigh impact
Quimilza (imsidolimab) remains under FDA review for generalized pustular psoriasis, with a PDUFA target action date of December 12, 2026. The event is company-specific and potentially material, but outcome risk is binary [#SEC-8K-2026-08-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology